Ephrin A1 ligand‐based CAR‐T cells for immunotherapy of EphA2‐positive cancer
Abstract Chimeric antigen receptor (CAR) T cells have demonstrated promising results in hematological malignancies; however, challenges remain in treating solid tumors.New CARs with more effectiveness and lower side effects are needed.Ephrin type‐A receptor 2 (EphA2) belongs to the Ephrin family of receptor tyrosine kinases, which is overexpresse